What is Altimmune's D&A?

Altimmune (ALT) reported D&A of $23K in Q1 2026.

How has Altimmune's D&A changed year-over-year?

Altimmune's D&A decreased by 20.7% year-over-year, from $29K to $23K.

What is the long-term trend for Altimmune's D&A?

Over 4 years (2021 to 2025), Altimmune's D&A has grown at a -32.9% compound annual growth rate (CAGR), from $551.3K to $112K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Altimmune ALT D&A

D&A at other companies

Eli LillyLLY

$509M+9.9%

Madrigal Pharmaceuticals, Inc.MDGL

$386K+1.8%

Wave Life SciencesWVE

$841K-3.9%

Delcath SystemsDCTH

$102K+137%

MeiraGTx Holdings plcMGTX

$3.01M-2.4%

Mirum Pharmaceuticals, Inc.MIRM

$6.87M+13.6%

Other financials

Income statement

See full

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

See full

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

See full

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Altimmune's D&A?: Altimmune (ALT) reported D&A of $23K in Q1 2026.
How has Altimmune's D&A changed year-over-year?: Altimmune's D&A decreased by 20.7% year-over-year, from $29K to $23K.
What is the long-term trend for Altimmune's D&A?: Over 4 years (2021 to 2025), Altimmune's D&A has grown at a -32.9% compound annual growth rate (CAGR), from $551.3K to $112K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.